Sitagliptin/metformin

Drug Profile

Sitagliptin/metformin

Alternative Names: Efficib; Januet; Janumet; Metformin/sitagliptin; MK-0431A; ONO 5434A; ONO-5435A; Ristfor; Sitagliptin and metformin HCl; Velmetia

Latest Information Update: 22 Mar 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antihyperglycaemics; Biguanides; Insulin sensitisers; Pyrazines; Small molecules; Triazoles
  • Mechanism of Action AMP activated protein kinase stimulants; CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 28 Feb 2017 Merck has patent protection for sitagliptin/metformin in Europe (Merck Annual report 2016)
  • 25 Sep 2015 Merck has patent protection for sitagliptin/metformin in USA (Merck 10-K, September 2015)
  • 03 Jun 2015 Launched for Type-2 diabetes mellitus in Vietnam, Indonesia, China, Taiwan, South Korea, Panama, Peru, Serbia, Kazakhstan, Egypt, Malta, Finland, Iceland, Lithuania, Latvia and Croatia (PO) before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top